23 results
8-K
EX-10.1
ADPT
Adaptive Biotechnologies Corp
12 Sep 22
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
8:45am
) any Product In-License or (f) any other investment that are or would be classified as investments on a balance sheet of such Person prepared
424B5
ylmmzj
16 Jul 20
Prospectus supplement for primary offering
4:26pm
424B5
hvtmon90d4bqsd61hz
14 Jul 20
Prospectus supplement for primary offering
5:01pm
10-K
9dvsf1divlsxc l74809
26 Feb 20
Annual report
4:53pm
424B4
qc41s
24 Jan 20
Prospectus supplement with pricing info
4:49pm
DRS
0sf5u9rp
9 Jan 20
Draft registration statement
12:00am
10-Q
msl8z 3i54bnkbw
13 Aug 19
Quarterly report
4:36pm
424B4
a0ig0t coahu
27 Jun 19
Prospectus supplement with pricing info
5:24pm
S-1
j2c76l5t499wmc50nedo
30 May 19
IPO registration
5:20pm
CORRESP
emiir6klr wnpvucph
30 May 19
Correspondence with SEC
12:00am
UPLOAD
atm86hozup il3382m
23 May 19
Letter from SEC
12:00am
DRSLTR
u3yla
8 May 19
Correspondence regarding draft registration statement
12:00am